Welcome to our dedicated page for Bluejay Diagnostics news (Ticker: BJDX), a resource for investors and traders seeking the latest updates and insights on Bluejay Diagnostics stock.
Bluejay Diagnostics Inc (BJDX) is a pioneer in rapid sepsis detection through its innovative Symphony™ platform, delivering critical IL-6 biomarker results in emergency care settings. This dedicated news hub provides investors and healthcare professionals with essential updates on regulatory milestones, clinical validations, and strategic partnerships.
Access authoritative information about BJDX's progress in transforming critical care diagnostics, including earnings reports, product development timelines, and peer-reviewed study outcomes. Our curated news collection simplifies tracking of FDA clearances, technology enhancements, and market expansion initiatives relevant to near-patient testing solutions.
Key updates include developments in sepsis triage protocols, Symphony platform deployments, and clinical utility studies demonstrating IL-6's prognostic value. Bookmark this page for real-time notifications about BJDX's advancements in cost-effective rapid diagnostics that support time-sensitive treatment decisions.
Bluejay Diagnostics (NASDAQ: BJDX) announced the pricing of an $8.75 million underwritten public offering. The offering includes 5,368,098 Common Units or Prefunded Units, each with one share of common stock or one pre-funded warrant and three types of warrants for additional stock purchases. The company set the purchase price for Common Units at $1.63 and Prefunded Units at $1.6299. Proceeds will be used to repay $2.3 million of outstanding debt, fund FDA approval-related activities, and support R&D and working capital. The offering is expected to close on June 28, 2024, with Aegis Capital Corp. as the underwriter.
Bluejay Diagnostics announced the primary results of their SYMON-I pilot clinical study, which suggests that interleukin-6 (IL-6) can predict mortality in sepsis and septic shock patients within 28 days of ICU admission. The study compared IL-6 levels to standard clinical tests like lactate and SOFA, finding IL-6 to be a more reliable predictor of mortality. The results will be validated in the SYMON-II study set to begin in Q3 2024. Positive results from SYMON-II could support a 510(k) application to the FDA in 2025. The company aims to present these results at scientific meetings and publish them in peer-reviewed journals, contingent on raising additional capital.
Bluejay Diagnostics announced a 1-for-8 reverse stock split effective June 20, 2024. This will reduce outstanding shares from approximately 4.5 million to around 564,000, with no change in par value. Fractional shares will be compensated in cash. The stock will trade under the same symbol, BJDX, but with a new CUSIP number. The reverse split affects all shareholders uniformly, preserving their percentage ownership except for fractional share adjustments. The transfer agent for this process is Continental Stock Transfer & Trust Company. Bluejay focuses on rapid diagnostics to improve patient outcomes in critical care settings.
FAQ
What is the current stock price of Bluejay Diagnostics (BJDX)?
What is the market cap of Bluejay Diagnostics (BJDX)?
